Cemiplimab maintenance for advanced adrenocortical carcinoma

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

This trial will test whether giving cemiplimab as maintenance immunotherapy after first-line EDP-M chemotherapy can delay progression in adults with advanced adrenocortical carcinoma who achieved a response or stable disease.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 31 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (other)
• Drugs / interventions: cemiplimab, prednisone, chemotherapy, immunotherapy, doxorubicin
• Locations: 1 site (Brescia, Brescia)
• Trial ID: NCT07085572 on ClinicalTrials.gov

What this trial studies

This single-arm, non-randomized prospective phase II trial gives cemiplimab, an anti–PD-1 immune checkpoint inhibitor, as maintenance therapy to adults with histologically confirmed ACC who have achieved response or disease stabilization after 4–6 cycles of first-line EDP-M chemotherapy. Patients may continue mitotane as clinically indicated while receiving cemiplimab and will be followed for disease progression and treatment safety. The study will collect clinical and laboratory data to explore which patients derive the most benefit and to monitor tolerability in combination with mitotane. The trial is conducted at ASST Spedali Civili di Brescia in Brescia, Italy.

Who should consider this trial

Good fit: Adults (≥18 years) with histologically confirmed ACC who had no progression after 4–6 cycles of EDP-M, have ECOG performance status 0–1, and adequate organ and marrow function are eligible.

Not a fit: Patients with disease progression after first-line EDP-M, ECOG ≥2, or significant organ dysfunction are unlikely to benefit from this maintenance approach.

Why it matters

Potential benefit: If successful, maintenance cemiplimab could prolong disease control and delay progression after first-line chemotherapy in advanced ACC.

How similar studies have performed: Prior studies of immune checkpoint inhibitors in metastatic ACC have produced durable responses in a small subset of patients, but overall benefit has been limited and not consistently predicted.

Eligibility criteria

Inclusion Criteria:

1. Male and females \>18 years of age;
2. Patients with histologically confirmed ACC;
3. Previous induction therapy with EDP-M followed by cytoreductive surgery if indicated;
4. No disease progression after first line 4-6 EDP-M cycles;
5. An ECOG PS of 0, 1;
6. Adequate organ and bone marrow function documented by:

   1. Hemoglobin \>9.0 g/dL
   2. ANC \>1.5 x 109/L
   3. Platelet count \>75 x 109/L
   4. Serum creatinine \<1.5 ULN or estimated CrCl \>30 mL/min
   5. Adequate hepatic function:

      * Total bilirubin \<1.5 x ULN;
      * AST and ALT both \<3 x ULN;
      * ALP \<2.5 x ULN; Note: For patients with Gilbert's syndrome, total bilirubin ≤3x ULN. Gilbert's syndrome must be documented appropriately as past medical history.
7. Women of child-bearing potential (physiologically capable of becoming pregnant) that must agree to follow instructions for methods of contraception (including at least one highly effective contraception method, see study protocol) for the duration of treatment with study drug, and after discontinuation of treatment as long as mitotane plasma levels are detectable and, in any case, at least for 6 months post treatment completion; must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug;
8. Women must not be breastfeeding;
9. Males that must agree to follow instructions for methods of contraception (see study protocol) for the duration of treatment with study drug, and then for a total of 6 months post treatment completion. In addition, male patients must not donate sperm for the time period specified above;
10. Willing and able to comply with clinic visits and study-related procedures;
11. Willing and able to provide informed consent signed by study patient or legally acceptable representative;
12. Able to understand and complete study-related questionnaires.

Exclusion Criteria:

1. History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 5 years;
2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor;
3. Administration of a live vaccine within 30 days of the first dose of study treatment;
4. Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs);
5. Diagnosis of immunodeficiency or systemic steroid therapy (i.e., dosing exceeding 10 mg of prednisone or equivalent). In case of mitotane treatment, a maximum steroid supplementation of 75 mg of cortone acetate (or equivalent hydrocortisone dose) will be accepted;
6. Uncontrolled HIV, Hepatitis B or Hepatitis C (see protocol for details);
7. History of (non-infectious) pneumonitis that required steroids or current pneumonitis;
8. Active infection requiring systemic therapy;
9. Significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty / stenting / bypass grafting within the last 6 months OR CHF NYHA Class II-IV or history of CHF NYHA Class III or IV;
10. Pregnancy or breastfeeding;
11. Continued sexual activity in women of childbearing potential (physiologically capable of becoming pregnant) or sexually active men who are unwilling to practice highly effective contraception (including at least one highly effective contraception method, see study protocol) prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose;
12. History of active tuberculosis (TB, Bacillus Tuberculosis);
13. Untreated brain metastasis that may be considered active.
14. Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.
15. Patients with a history of solid organ transplant (exception: corneal transplant)
16. Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.
17. ECOG PS ≥ 2

Where this trial is running

Brescia, Brescia

• S.C. Oncologia - ASST Spedali Civili di Brescia — Brescia, Brescia, Italy (RECRUITING)

Study contacts

• Principal investigator: Alfredo Berruti, Prof, MD — ASST Spedali Civili di Brescia and University of Brescia
• Study coordinator: Aldo Roccaro, MD, PhD

Conditions: Adrenal Cortical Carcinoma